Luca Gianni
Milan oncologist who led NeoSphere, the trial that showed adding pertuzumab to trastuzumab and docetaxel before surgery clears more HER2-positive breast cancers, the basis for pertuzumab's neoadjuvant approval.
Overview
Luca Gianni led medical oncology at the Istituto Nazionale dei Tumori and then at San Raffaele Hospital in Milan, and now leads the Fondazione Michelangelo. He was first author of the 2012 Lancet Oncology report of NeoSphere, the phase 2 trial in which pertuzumab plus trastuzumab and docetaxel produced a higher pathological complete response rate than trastuzumab and docetaxel, and of the NOAH trial of neoadjuvant trastuzumab. His trials helped establish pathological complete response as an endpoint for accelerated approval.
Similar pages
not linked directly; found by shared links- PersonRashmi K. Murthy
Shares HER2-positive breast cancer and the tags breast, trialist.
- PersonGabriel N. Hortobagyi
Shares the tags breast, trialist.
- PersonStephen Johnston
Shares the tags breast, trialist.
- PersonJosé Baselga
Shares HER2-positive breast cancer and the tags breast, trialist.
- PersonSandra M. Swain
Shares HER2-positive breast cancer and the tags breast, trialist.
- PersonRupert Bartsch
Shares HER2-positive breast cancer and the tags breast, trialist.
- PersonAditya Bardia
Shares the tags breast, trialist.
- PersonAndrea DeCensi
Shares the tags breast, trialist.